Article Information
History
- May 8, 2018.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Annelyn Torres-Reverón, PhD1,
- Leslie L. Rivera-Lopez, BS1,
- Idhaliz Flores, PhD2,3 and
- Caroline B. Appleyard, PhD2,4
- 1Dept. of Biomedical Sciences, Division of Neuroscience, and Dept. of Human Genetics, University of Texas at Rio Grande Valley, School of Medicine, Edinburg, Texas
- 2Division of Basic Sciences, Ponce Health Sciences University - Ponce Research Institute, Ponce, Puerto Rico
- 3Dept. of Obstetrics and Gynecology, Ponce Health Sciences University, School of Medicine, Ponce, Puerto Rico
- 4Dept. of Internal Medicine, Ponce Health Sciences University, School of Medicine, Ponce Puerto Rico
- Corresponding Author:
Annelyn Torres-Reveron, PhD, University of Texas at Rio Grande Valley, School of Medicine, 1214 W Schunior Street, Edinburg TX 78541, P: +1-956-665-3144, E: annelyn.torresreveron{at}utrgv.edu
Posted May 08, 2018.
Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis
